Lv3
390 积分 2021-08-31 加入
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
9天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
9天前
已完结
Triple-Negative Breast Cancer
15天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
17天前
已完结
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
22天前
已完结
Sacituzumab Govitecan in Metastatic Breast Cancer
1个月前
已关闭
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
1个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
1个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
